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Background: Cerebral ischemia results in enhanced expression of contractile cerebrovascular receptors, such as
endothelin type B (ETB), 5-hydroxytryptamine type 1B (5-HT1B), angiotensin II type 1 (AT1) and thromboxane (TP)
receptors in the cerebral arteries within the ischemic area. The receptor upregulation occurs via activation of the
mitogen-activated protein kinases (MAPK) pathway. Previous studies have shown that inhibitors of the MAPK
pathway diminished the ischemic area and contractile cerebrovascular receptors after experimental cerebral
ischemia. The aim of this study was to examine if the upregulation of contractile cerebrovascular receptors after
48 h of organ culture of human cerebral arteries involves MAPK pathways and if it can be prevented by a MEK1/2
inhibitor. Human cerebral arteries were obtained from patients undergoing intracranial tumor surgery. The vessels
were divided into ring segments and incubated for 48 h in the presence or absence of the specific MEK1/2
inhibitor U0126. The vessels were then examined by using in vitro pharmacological methods and protein
immunohistochemistry.
Results: After organ culture of the cerebral arteries the contractile responses to endothelin (ET)-1, angiotensin (Ang)
II and thromboxane (TP) were enhanced in comparison with fresh human arteries. However,
5-carboxamidotryptamine (5-CT) induced decreased contractile responses after organ culture as compared to fresh
arteries. Incubation with U0126 diminished the maximum contraction elicited by application of ET-1, Ang II and
U46619 in human cerebral arteries. In addition, the MEK1/2 inhibitor decreased the contractile response to 5-CT.
Immunohistochemistry revealed that organ culture resulted in increased expression of endothelin ETA, endothelin
ETB angiotensin AT2, 5-hydroxytryptamine 5-HT1B and thromboxane A2 receptors, and elevated levels of activated
pERK1/2, all localized to the smooth muscle cells of the cerebral arteries. Co-incubation with U0126 normalized
these proteins.
Conclusion: The study demonstrated that there is a clear association between human cerebrovascular receptor
upregulation via transcription involving activation of the MAPK pathway after organ culture. Inhibition of the MAPK
pathways attenuated the vasoconstriction mediated by ET, AT and TP receptors in human cerebral arteries and the
enhanced expression of their receptors. The results indicate that MAPK inhibition might be a novel target for
treatment of cerebrovascular disorders.
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Large efforts have during the last few decades been
made to understand the intracellular mechanisms
involved in ischemia-induced cerebral damage and to
develop drugs that protect the brain from damage once
a stroke has occurred. However, despite extensive re-
search into genetics and molecular biology associated
with cerebral ischemia, few acute therapies have proven
effective in the clinic [1]. Investigations have revealed
that cerebral ischemia is accompanied by modifications
in the expression of genes regulating receptor expres-
sions in cerebrovascular smooth muscle cell (SMC)s
associated with the cerebral ischemia [2]. Thus, experi-
mental and clinical studies of cerebral ischemia have
reported increased levels of the potent vasoconstrictor
substances endothelin (ET) [3,4], 5-hydroxytryptamine
(5-HT) [5,6], angiotensin (Ang II) [7] and thromboxane
(TXA2) [8,9]. ET-1, 5-HT, Ang II and TXA2 are all po-
tent vasoconstrictors of cerebral arteries that mediate
effects through the family of G-protein coupled recep-
tors (GPCRs) [10,11]; endothelin A (ETA), endothelin
B (ETB) [11,12], 5-HT receptors [5], the angiotensin II
type 1 (AT1) and type 2 (AT2) receptors [13,14] and the
thromboxane receptor (TP) [15].
Cerebral ischemia is multifactorial, involves a number
of neuronal and glial mechanisms; however, several cere-
brovascular receptors are in addition involved in the
pathophysiology of cerebral ischemia. There is upregula-
tion (enhanced expression) of contractile ETB, 5-HT1B,
AT1 and TP receptors in major cerebral arteries from
experimental focal and global ischemia, via enhanced
transcription and translation [16-24]. This upregulation
of cerebrovascular receptors leads to enhanced vasocon-
striction and correlates with reduction in regional cere-
bral blood flow (rCBF) and degree of neurology deficit
[21]. Blockade of the individual subtypes of receptors
involved might prevent or reduce the cerebral ischemia
to a certain degree; we hypothesize that treatment aimed
at a common signaling pathway would be more benefi-
cial by avoiding the administration of several antagonists
with circulatory consequences.
The mitogen-activated protein kinase (MAPK) pathways
are implicated in neuronal death and survival after stroke.
A time study of the alteration in cerebrovascular MAPKs
after experimental subarachnoid hemorrhage (SAH)
revealed that there was early (within minutes) and sustained
activation of the specific extracellular signal-regulated
kinases (ERK)1/2 pathway, while the p38 and JNK pathways
were activated first at 48 hours [25]. The ERK1/2 pathway
can be inhibited at various points upstream such as at ras-
raf-MEK1/2; inhibition of this pathway with a specific
MEK1/2 (the MAPKK of ERK1/2) inhibitor abolished the
receptor upregulation as well as preventing the CBF reduc-
tion and diminishes the infarct [16,26,27]. ERK1/2 belongsto the family of MAPK and is phosphorylated and thereby
activated by the MAP kinase/ERK kinase (MEK)1/2. Several
studies have shown an involvement of the MEK/ERK1/2
signalling pathway in cerebral ischemia [26,28].
Organ culture is an in vitro method for investigating cel-
lular mechanisms involved in upregulation of vasocontrac-
tile G-protein coupled receptors. Organ culture is not a
model for stroke, however, changes in vasoconstrictor
responses after in vitro organ culture show a remarkable
similarity to changes observed in animal models of ische-
mic and hemorrhagic stroke. Thus, there is an upregulation
of contractile G-protein receptors after SAH [21] and focal
ischemia [22,23] which also is observed in organ culture
[29]. This make the organ culture model an appropriate
model for investigating the pharmacological characteristics
and underlying molecular and cellular mechanism involved
in the upregulation of vasocontractile G-protein coupled
receptors. The upregulation of contractile receptors in the
SMCs are prevented with MAPK inhibitor both in organ
culture [29] and experimental stroke [27,30].
In the design of future cerebrovascular therapeutics it is
important that the intracellular mechanisms are charac-
terised in human subjects. Here we hypothesize that there
is an upregulation of contractile cerebrovascular receptors
after 48 h of organ culture in human cerebral arteries and
that this upregulation occurs via the MAPK ERK1/2 path-
way and can be inhibited by the MEK1/2 inhibitor U0126.
Methods
All procedures were carried out strictly within national laws
and guidelines and approved by the Ethical Committee at
the University of Lund (LU-818-01) and has been per-
formed in accordance with the Declaration of Helsinki. A
consent was obtained from the participants prior to
surgery.
Tissue collection and organ culture procedure
Cortical arteries were obtained from patients undergoing
neurological surgery for brain tumors. The arteries
obtained were physiological arteries with surrounded
tumor tissue, the arteries were carefully dissected free of
connective tissue leaving the vessel with intact intima,
media and adventitia. The arteries were immediately
immersed in cold sterile Dulbecco’s modified Eagle’s
medium (DMEM,Gibco, Invitrogen, Carlsbad, CA, USA)
and transported to the laboratory. The arteries were cut
into 1-mm long ring segments for in vitro pharmaco-
logical experiments and 3-mm for immunohistochemis-
try. The outer diameters were between 300 and 800 μm.
Organ culture
The arterial segments were cultured for 48 hours at 37°C
in humidified 5% CO2 and air in Dulbecco’s modified
Eagle’s medium supplemented with pencillin (100 U/ml),
Figure 1 Negative control; omission of the primary antibody or
only the primary antibody applied. No immunoreactivity is
detected within the smooth muscle cell layer (arrow points). Only
auto-fluorescence in lamina elastica interna (arrow) is detected. LEI;
lamina elastica interna. Vascular wall structures; example of
immunohistochemical staining on human artery showing the
different wall structures. ADV; adventitial layer, LEI; lamina elastica
interna, SML; smooth muscle cell layer.
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The method of blood vessel culture has been described
previously [31]. The segments were cultured in the
absence or presence of the MEK1/2 inhibitors U0126
(5 μM). The selection of the inhibitor U0126 was based
on previous detailed work on isolated arteries in organ
culture, were U0126 was demonstrated to be the best of
all available MEK1/2 inhibitors to inhibit the GPCRs and
MAPK pathway [29,32].
In vitro pharmacology myograph experiments
For contractile experiments a sensitive myograph was
used for recording the isometric tension in isolated cere-
bral arteries [33,34]. The vessels were cut into 1 mm long
cylindrical segments and mounted on two 40 μm in diam-
eter stainless steel wires in a Myograph (Danish Myo
Technology A/S, Denmark). One wire was connected to a
force displacement transducer attached to an analogue-
digital converter unit (ADInstruments, Oxford, UK). The
other wire was connected to a micrometer screw, allowing
fine adjustments of vascular tone by varying the distance
between the wires. Measurements were recorded on a
computer by use of a PowerLab unit (ADInstruments).
The segments were immersed in a temperature controlled
buffer solution (37°C) of the following composition (mM)
NaCl 119, NaHCO3 15, KCl 4.6, MgCl2 1.2, NaH2PO4 1.2,
CaCl2 1.5 and glucose 5.5. The buffer was continuously
aerated with oxygen enriched with 5% CO2 resulting in a
pH of 7.4. Initially, the vessel segments were normalized
and set to an initial resting tone of 2 mN that is the tone
that it would have if relaxed and under a transmural pre-
rssure of 100 mmHg. The vessels were allowed to stabilize
at this tone for 1 hour. The contractile capacity was deter-
mined by exposing the vessels to an isotonic solution con-
taining 63.5 mM of K+, obtained by partial change of
NaCl for KCl in the above buffer. The contraction induced
by K+ was used as reference for the contractile capacity
[34]. Only vessels responding by contraction of at least 2
mN to potassium were included in the study.
Concentration-response curves were obtained by cu-
mulative application of 5-carboxamidotryptamine (5-CT;
specific 5-HT1 receptor agonist (Sigma, St. Louis, USA))
in the concentration range 10 –12 to 10 –5 M, ET-1
(Endothelin ETA and ETB receptor agonist (AnaSpec,
San Jose, USA)) in the concentration range 10 –14 to
10 –7 M, U46619 (Thromboxane A2 receptor agonist
(Sigma, St. Louis, USA)) in the concentration range
10 –12 to 10 –6 M and Ang II (Angiotensin AT1 and ATII
receptor agonist (Sigma, St. Louis, USA)) in the concen-
tration range 10 –12 to 10 –6 M.
Immunohistochemistry
For immunofluorescence the cerebral artery segments were
embedded in Tissue TEK (Gibo, Invitrogen A/S, Taastrup,Denmark), frozen at -80°C and subsequently sectioned into
10 μm thick slices. Cryostat sections were fixed for 10 min-
utes in ice-cold acetone (−20°C) and thereafter rehydrated
in phosphate buffered-saline (PBS, pH 7.2) containing
0.25% Triton X-100 (PBST), for 3×5 minutes. The sections
were then permeabilized and blocked for 1 h in blocking
solution containing PBS and 5% normal donkey serum and
then incubated over night at 4°C with either of the follow-
ing primary antibodies; rabbit anti ETA (1:50, Santa Cruz
Biotechnology, CA, U.S.A., sc-33535), rabbit anti ETB
(1:200, Abcam, Cambridge, UK, ab1921), rabbit anti AT1
(1:100, Santa Cruz Biotechnology, sc-1173), AT2 (1:100,
Santa Cruz Biotechnology, sc-9040), 5-HT1B (1:100, Santa
Cruz Biotechnology, sc-1460), rabbit TP-receptor (1:100,
Cayman Chemical company, Michigan, U.S.A., 10004452)
and rabbit anti phospho-ERK p44/42 MAPK (1:50, Cell
Signaling Technology, Beverly, CA, U.S.A., #4376). The
primary antibodies were diluted in PBST, 1% bovine
serum albumin (BSA) and 3% normal donkey serum.
On the second day sections were rinsed in PBST for
3×15 minutes and incubated with the secondary anti-
body (1 h, room-temperature). The secondary antibody
used was Cy™2 conjugated donkey anti rabbit (1:200,
Jackson ImmunoResearch, West Grove, PA, U.S.A,
711-165-152) diluted in PBST and 1% BSA. The sec-
tions were washed subsequently with PBST and
mounted with Crystal mounting medium (Sigma, St.
Louis, MO, U.S.A). Immunoreactivity was visualized
with an Olympus Microscope (BX 60, Japan) at the
appropriate wavelength. Negative controls for all anti-
bodies were made by omitting primary antibodies.
In all cases, no specific staining was found; only
auto-fluorescence in lamina elastica interna was seen
(Figure 1). To evaluate the auto-fluorescence in lam-
ina elastica interna, controls were made with only pri-
mary antibodies.
Table 1 Contractile effects of ET-1, U46619, Ang II and
5-CT in human cerebral arteries







Control 6 6.76 ± 1.32 107 ± 12a 7.20 ± 0.89
Organ Culture 6 4.37 ± 1.21 143 ± 22 a,b 8.74 ± 0.25
Organ Culture + U0126 7 3.53 ± 0,90 57 ± 8 b 8.49 ± 0,10
U46619
Control 7 8.26 ± 1.98 102 ± 15a 7.35 ± 0.74
Organ Culture 7 5.10 ± 1.60 141 ± 11a,b 7.18 ± 0.18
Organ Culture + U0126 4 3.65 ± 1.89 76 ± 40b 6.64 ± 0.10
Ang II
Control 6 1.67 ± 0.54 12 ± 2a
Organ Culture 5 4.44 ± 1.92 43 ± 12a,b 9.15 ± 0.82
Organ Culture + U0126 4 4.46 ± 2.41 1 ± 1b 9.05 ± 1.13
5-CT
Control 6 6.76 ± 1.36 50 ± 8 7.45 ± 0.66
Organ Culture 4 3.90 ± 1.59 17 ± 5b 7.35 ± 1.21
Organ Culture + U0126 7 3.53 ± 0.90 2 ± 1b 7.38 ± 0.73
Responses were characterized by Emax values, expressed as percent of
63 mM K+ -induced contraction, and pEC50 values (negative logarithm of the
molar concentration that produces half maximum contraction). Values are
represented as mean ± s.e.m and n represents number of patients.
a = significant difference between organ culture and control groups,
b = significant difference between organ culture and organ culture treated
with U0126.
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Data are expressed as mean ± standard error of the
mean (s.e.m.), and n refers to the number of patients.
Statistical analyses were performed with Kruskal-Wallis
non-parametric test with Dunn’s post-hoc test, where
P<0.05 was considered significant.
In vitro pharmacology
Contractile responses in each segment are expressed as per-
centage of the 63.5 mM K+ induced contraction. Emax value
represents the maximum contractile response elicited by an
agonist and the pEC50 the negative logarithm of the drug
concentration that elicited half the maximum response.
Immunohistochemistry
Measurements were made in order to quantify the immu-
noreactivity of the protein expressions in the different
groups. The evaluation of receptors and pERK expression
was performed by measurements of the fluorescence inten-
sity using the software image J http://rsb.info.nih.gov/ij/.
The immunoreactivity of the individual receptors was
visualized with the same microscope settings during the
same day for all groups. The intensity measurements were
performed in a blinded manner. The fluorescence intensity
was measured in four given areas in the smooth muscle
layer of each sample (always clockwise). Values were given
by dividing the fluorescence intensity to measured area of
each sample. These values are presented as percentage
fluorescence in the cultured groups compared to the fresh
groups (henceforth only mentioned as control), where the
fresh (control) group is set to 100%.
Results
Functional in vitro pharmacology
K+ -induced contraction, Emax, and pEC50 values for
respective group are presented in Table 1. Of all vessels
tested 72% responded to a K+ -induced contraction.
ET-1 receptor
Contractile response to ET-1
In cultured arteries ET-1 yielded contractions with an
Emax of 143 ± 22% and a pEC50 of 8.74 ± 0.25. These
values were significantly higher than those observed in
control arterial segments, in which an Emax of 107 ± 12%
was observed. This is in accordance with previous results,
which show a similar upregulation in human cerebral
arteries after organ culture [35]. The presence of U0126
during the organ culture produced a significantly attenu-
ated ET-1 induced response, with an Emax of 57 ± 8%
compared to the cultured arteries (Figure 2A, Table 1).
Protein expression examined by immunohistochemistry
The ETA receptor protein was increased after organ
culture (137 ± 3%) as compared to control (100 ± 4%).Incubation with U0126 prevented the increased expres-
sion of ETA (107 ± 4%) receptor protein on the smooth
muscle cells (Figure 2B and 2D, Table 2). In addition, the
ETB receptor protein was expressed in the smooth
muscle cells and this signal was increased in organ cul-
ture (128 ± 3%) as compared to control arteries (100 ±
6%). Treatment with the MEK1/2 inhibitor U0126 pre-
vented the upregulation of ETB (80 ± 4%), receptor pro-
tein levels in the smooth muscle cell layer as compared
to the organ culture (Figure 2C, 2D Table 2).Thromboxane receptor
Contractile response
In cultured arteries U46619 yielded contractions with an
Emax of 141 ± 11%. This value was significantly higher
than those observed in control arterial segments, in
which an Emax of 102 ± 15% was observed (Figure 3A).
The presence of the MEK1/2 inhibitor U0126 during
the organ culture produced a significantly attenuated
U46619 contractile response, compared to the cultured
arteries. There was no significant difference in the Emax
between control arteries and cultured arteries treated
with U0126 (Figure 3A, Table 1).
Figure 2 (See legend on next page.)
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Figure 2 A. Concentration response curves elicited by cumulative application of ET-1 in human cerebral arteries incubated for 48 h
with or without the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. The responses to ET-1 are clearly increased in the
incubated arteries as compared to control arteries. The enhanced contraction observed after organ culture was inhibited in arteries cultured with
U0126. Data are expressed as mean ± s.e.m and n refer to the number of patients used. B and C Sections from the human cerebral artery
showing ETA and ETB receptor immunoreactivity in the smooth muscle cell layer. D Expression of ETA and ETB protein levels in human cerebral
arteries incubated for 48 h with or without the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as percentage of
control and given as mean ± s.e.m. *P<0.05, ** P<0.01.
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The TP receptor protein was expressed in the smooth
muscle cells and this signal was slightly increased in
organ culture (119 ± 5%) as compared to control arteries
(100 ± 3%). Treatment with the MEK1/2 inhibitor
U0126 prevented the upregulation of TP (106 ± 3%), re-
ceptor protein levels in the smooth muscle cell layer as
compared to the organ culture, however not significantly
(Figure 3B-C and Table 2).
Angiotensin receptor
Contractile response to Ang II
In cultured arteries Ang II induced a concentration-
dependent contraction with an Emax of 43 ± 15% and a
pEC50 of 9.15 ± 1.65. These values were significantly
higher than those observed in control arterial segments,
in which an Emax of 12 ± 2% of was observed
(Figure 4A, Table 1). The presence of U0126 during the
organ culture produced a significantly attenuated Ang II
induced response, compared to the cultured arteries.
Interestingly there was no significant difference in the
contractile response between control arteries and cul-







ETB (%) ± s.e.m 100 ± 6
a
128 ± 3 a, b 80 ± 4 b
ETA (%) ± s.e.m 100 ± 4
a
137 ± 3 a, b 107 ± 4 b
TP (%) ± s.e.m 100 ± 3 119 ± 5 106 ± 3
AT1 (%) ± s.e.m 100 ± 2
a
62 ± 4 a 82 ± 7
AT2 (%) ± s.e.m 100 ± 2
a
120± 2 a 111 ± 1
5-HT1B (%) ± s.e.m 100 ± 6
a
128 ± 3 a, b 84 ± 4 b
pERK1/2 (%) ± s.e.m 100 ± 2
a
128 ± 2 a,b 86 ± 2 b
Activation of the different protein levels measured with
immunohistochemistry in human arteries. Values are expressed as percentage
of control and given as mean ± s.e.m. a = significant difference between organ
culture and control groups, b = significant difference between organ culture
and organ culture treated with U0126.In the presence of the AT2 receptor antagonist PD12319
there was a diminished contraction after organ culture
compared to control arteries, suggesting that the AT2
receptors are responsible for the upregulated responses
induced by organ culture (data not shown).
Protein expression examined with immunohistochemistry
Immunohistochemistry showed a decrease in AT1 recep-
tor protein in the smooth muscle cells after organ cul-
ture (62 ± 4%) as compared to control (100 ± 2%).
Treatment with the MEK1/2 inhibitor U0126 prevented
the down regulation of AT1 (82 ± 7%), receptor protein
levels in the smooth muscle cell layer as compared to
the organ culture (Figure 4B and 4D). The AT2 receptor
protein was increased after organ culture (119 ± 2%) as
compared to control (100 ± 2%). Incubation with U0126
prevented the increased expression of AT2 (111 ± 3%)
receptor protein on the smooth muscle cells, however
not significantly (Figure 4C-D, Table 2).
5-HT1B receptor
Contractile response
In cultured arteries 5-CT yielded significantly lower con-
tractions that those observed in control arterial seg-
ments, presence of U0126 during the organ culture
produced a significantly attenuated 5-CT induced re-
sponse, compared to the cultured arteries (Figure 5A).
Protein expression examined by immunohistochemistry
The 5-HT1B receptor protein was expressed in the
smooth muscle cells and this signal was increased in
organ culture (128 ± 3%) as compared to control (100 ±
6%). Treatment with the MEK1/2 inhibitor U0126 pre-
vented the upregulation of 5-HT1B (84 ± 4%), receptor
protein levels in the smooth muscle cell layer as com-
pared to the organ culture (Figure 5B-C, Table 2).
pERK1/2
Protein expression examined by immunohistochemistry
The pERK1/2 protein was expressed in the smooth
muscle cells and this signal was increased in organ cul-
ture (128 ± 2%) as compared to control (100 ± 2%).
Treatment with the MEK1/2 inhibitor U0126 prevented
the upregulation of pERK1/2 (86 ± 2%), protein levels in
Figure 3 A. Concentration response curves elicited by cumulative application of U46619 in human cerebral arteries incubated for 48 h,
human cerebral arteries incubated for 48 h with the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as
mean ± s.e.m. B. Sections from the human cerebral artery showing TP receptor immunoreactivity in the smooth muscle cell layer.
C. Expression of TP protein levels in human cerebral arteries incubated for 48 h with or without the MEK1/2 inhibitor U0126 (5 μM) and control
human arteries. Data are expressed as percentage of fresh and given as mean ± s.e.m. *P<0.05, ** P<0.01.
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culture (Figure 6A-B).
Discussion
This study demonstrates that there is a clear association
between human cerebrovascular receptor upregulation
via transcription involving activation of the MAPK path-
way after organ culture. This was shown by the close
association between pERK1/2 activation and the enhanced
expression of the contractile receptors at both protein
level and at a functional level.The study design was based on previous work that has
shown that organ culture induces upregulation of cerebro-
vascular receptors in a manner similar as that observed in
experimental SAH and MCAO [36,37]. Organ culture is
not a model for stroke, however, changes in vasocon-
strictor responses after in vitro organ culture show a re-
markable similarity to changes observed in animal models
of ischemic and hemorrhagic stroke, which makes organ
culture a useful in vitro method to study the pharmaco-
logical characteristics and underlying molecular and cellu-
lar mechanism of cerebrovascular receptor alterations.
Figure 4 A. Concentration response curves elicited by cumulative application of Ang II in human cerebral arteries incubated for 48 h,
human cerebral arteries incubated for 48 h with the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as
mean ± s.e.m. B and C. Sections from the human cerebral artery showing AT1, and AT2 receptor immunoreactivity in the smooth muscle cell
layer. D. Expression of AT1 and AT2 protein levels in human cerebral arteries incubated for 48 h with or without the MEK1/2 inhibitor U0126
(5 μM) and control human arteries. Data are expressed as percentage of fresh and given as mean ± s.e.m. *P<0.05, ** P<0.01.
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Figure 5 A. Concentration response curves elicited by cumulative application of 5-CT in human cerebral arteries incubated for 48 h,
human cerebral arteries incubated for 48 h with the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as
mean ± s.e.m. B. Sections from the human cerebral artery showing 5-HT1B receptor immunoreactivity in the smooth muscle cell layer.
C. Expression of 5-HT1B protein levels in human cerebral arteries incubated for 48 h with or without the MEK1/2 inhibitor U0126 (5 μM)
and control human arteries. Data are expressed as percentage of fresh and given as mean ± s.e.m. *P<0.05, ** P<0.01.
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levels of several cerebrovascular receptor types ETA,
ETB, AT1, AT2 and 5-HT1B [38] and hence is in agree-
ment with the experimental data obtained in animals.
The present study revealed several novel and important
findings: (i) While the contractile responses to ET-1 usu-
ally means activation of the ETA receptors we found that
there is an interaction between the ETA and ETB recep-
tors in cerebral arteries following SAH both in experi-
mental studies and in organ culture of human brain
vessels [19,35]. The present immunohistochemistry pro-
vide experimental evidence that both ETA and ETBreceptors are upregulated after organ culture. (ii) The
angiotensin II responses were increased. Contrary to ani-
mal data the responses were unaltered by specific angio-
tensin AT1 blockers [22]. In animal models of stroke an
upregulation of the contractile response to Ang II is
observed and this contraction is mediated by the AT1
receptor [22,36]. In our study in the human arteries the
results showed that in presence of the AT2 receptor
antagonist PD12319 there was a diminished contraction
after organ culture compared to control arteries, sug-
gesting that the AT2 receptors are responsible for the
upregulated responses induced by organ culture. Since
Figure 6 A. Sections from the human cerebral artery showing pERK immunoreactivity in the smooth muscle cell layer. There are
increased expressions of the ERK1/2 protein levels in the cultured arteries compared to the control segments. Treatment with U0126 prevented
the increased protein expression in the smooth muscle cells. B. Expression of pERK1/2 protein levels in human cerebral arteries incubated for
48 h with or without the MEK1/2 inhibitor U0126 (5 μM) and control human arteries. Data are expressed as percentage of fresh and given as
mean ± s.e.m. *P<0.05, ** P<0.01.
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AT2 receptor protein that was elevated in the cerebral
artery smooth muscle cells the evidence suggests that
there is de novo upregulation of AT2 receptors produ-
cing contraction in the human brain arteries after organ
culture. (iii) The 5-HT responses were reduced by organ
culture, a finding in concert with what we have seen in
tMCAO using two different models as well as after 24 h
of organ culture.
Although the decrease in 5-HT1B-mediated contractile
responses are less pronounced after organ culture than
after experimental stroke [37]. In the subarachnoid
hemorrhage model and global ischemia we have demon-
strated an upregulation of the 5-HT1B receptor [20,39].
Hence, whereas smooth muscle ETB receptors are upre-
gulated after all types of cerebral ischemia investigated
so far (subarachnoid hemorrhage, global cerebral ische-
mia, and focal cerebral ischemia) as well as after organ
culture, changes in the expression of the 5-HT1B recep-
tor appear to vary with the type of cerebral ischemia.
The role of 5-HT and its receptor in ischemia are not
clear; while some studies report a protective role for5-HT receptor agonists, others show increased contract-
ility and improvement with 5-HT receptor antagonist
[40,41]. The results from the study of TP receptors
revealed an increased response to the agonist but no sig-
nificant upregulation of receptor protein. In experimen-
tal SAH a similar type of reaction appears [24]. The
GPCR changes that we have observed in the human
cerebral arteries after organ culture show a striking simi-
larity to the changes observed in experimental cerebral
ischemia and thus complements the picture of reactions.
Early during organ culture the raf-MEK-ERK pathway
is activated and remains activated during the first two
days of culture [32]. Other MAPK members such as p38
and JNK may also be activated but this seems to occur
later during organ culture. Detailed study of major cere-
bral arteries and intracerebral microvessels were per-
formed following experimental SAH [25]; the results
clearly demonstrated that the MEK/ERK1/2 pathway
was activated within minutes and remained activated
until end of the 48 h period. On the other hand p38 and
JNK reached significance only at 48 h. This is a model of
SAH, however, a similar phenomenon was observed after
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both in large cerebral arteries and in microvessels within
the brain tissue [42]. In the present study we verified
that organ culture results in enhanced expression of
pERK1/2 in the smooth muscle cells. Co-administration
of the specific MEK1/2 inhibitor U0126 abolished this,
confirming that the MEK/ERK pathway is important.
In cultured human arteries, the specific blockade of
the MAPK MEK1/2 activity abolished the vascular
smooth muscle cell receptor upregulation. A number of
mechanisms and receptors have been proposed to ac-
count for the late cerebral ischemia [43] but no drug
exist with good effect. Clazosentan, an endothelin recep-
tor antagonist, was in a recent clinical study shown to
result in reduction in vasospasm as seen angiographi-
cally but the outcome was not altered [44]. This was
taken as evidence that we may consider also other events
than just arterial narrowing; early brain injury and cor-
tical spreading depression. We propose that cerebrovas-
cular receptor upregulation may be such a mechanism
that could be of importance, the current study reveals a
mechanism present in man that can be modified with
inhibition of raf-MEK-ERK signaling.
Conclusion
In conclusion, we show that specific inhibition of the
MAPK pathway using U0126 significantly attenuates the
vasoconstriction mediated by ET, AT and TP receptors in
human cerebral arteries and the enhanced expression of
their receptors. The results indicate that MAPK inhibition
might be a novel target for treatment of cerebrovascular
disorders.
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